Merck, HPV vaccine

Merck opens $1 billion addition in north Durham to boost production of popular vaccine
The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a 225,000-square-foot addition to the company’s existing campus off Old Oxford Road.
Merck opens $1B vaccine production facility (updated)
According to the company, the new, 225,000-square-foot expansion is a "crucial component" of a more than $12 billion infusion toward U.S. capital investments it's made since 2018.
Drugmaker Merck opens state-of-art $1B facility to manufacture HPV Gardasil, other vaccines
Drugmaker Merck announced Tuesday the opening of a new facility in North Durham. The $1 billion plant will manufacture the HPV vaccines Gardasil and Gardasil 9, while the site continues to produce vaccines against measles,
Merck opens $1B Gardasil manufacturing facility in North Carolina
At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated to produce bulk substance for its megablockbuster HPV vaccine Gardasil.
Merck opens $1B vaccine plant in North Carolina
Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S.
Merck opens manufacturing facility in North Carolina amid Trump's tariff threats
Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid President Donald Trump's tariff threats.
Merck Opens Vaccine Manufacturing Facility in North Carolina
Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, as the drugmaker seeks to boost its U.S. manufacturing in the face of President Donald Trump's tariff threats. Drugmakers have been exploring the possibility of government-granted exemptions for domestically manufactured medicines since Trump has threatened to impose 25% tariff on pharmaceutical imports.
Just The News6d
Merck virologist recalls becoming whistleblower over maker's blockbuster MMR measles, mumps vaccine
Stephen Krahling was a published cancer researcher when vaccine maker Merck brought him on board as a virologist in 1999. That’s when he says he found himself embroiled in an all-hands-on-deck ...
Sharyl Attkisson: An interview with MMR vaccine whistleblower Stephen Krahling
Scientist Stephen Krahling worked on a project at Merck called “Protocol 7” and was uniquely positioned to blow the whistle on what he learned.
Merck prevails in US safety litigation over Gardasil HPV vaccine
A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent ...
Fierce Pharma1d
Merck defeats claims it should have added safety warnings to Gardasil's label, knocking out 200-plus lawsuits
In a decision signed Monday, North Carolina federal judge Kenneth Bell granted Merck’s motion to dismiss the claims of ...
BioSpace1d
Good Day for Gardasil as Merck Wins Safety Suit, Drops $1B for Manufacturing Push
According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of ...
Merck prevails in Gardasil safety litigation
A federal judge has ruled in favor of Merck in litigation accusing the drugmaker of concealing the risks of Gardasil, a ...
Why Merck & Co., Inc. (MRK) is the Best Pharma Stock to Buy According to Hedge Funds
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other ...